The process of splicing can cause cancer cells with mutations in genes, such as BRCA1, to become resistant to PARPi treatment ...

Researchers from Tango Therapeutics Inc. have unveiled DNA ligase 1 (LIG1) as a potential new therapeutic target for synthetic lethality in BRCA1-mutant cancers after CRISPR/Cas9 screening.

Certain inherited gene mutations, like those in the BRCA1 and BRCA2 genes, can dramatically increase the likelihood of developing cancers such as breast and ovarian cancer. Conditions like Lynch ...